Paradoxically, it is well known that the abundance of MYC oncoprotein closely correlates with chemoresistance in many tumor types, including prostate cancer, ovarian cancer, melanoma, lung cancer, and hepatocellular carcinoma both in vitro and in vivo [33,113,114,115,116]. This evidence concerns the gene MYC and Familial prostate cancer.